JPMorgan Chase & Co. trimmed its holdings in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 79.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 78,100 shares of the medical instruments supplier’s stock after selling 305,778 shares during the quarter. JPMorgan Chase & Co. owned 0.21% of AngioDynamics worth $1,266,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. State of Alaska Department of Revenue increased its position in shares of AngioDynamics by 91.7% during the 2nd quarter. State of Alaska Department of Revenue now owns 6,768 shares of the medical instruments supplier’s stock worth $109,000 after purchasing an additional 3,238 shares during the last quarter. Teachers Retirement System of The State of Kentucky increased its position in shares of AngioDynamics by 77.5% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 7,100 shares of the medical instruments supplier’s stock worth $123,000 after purchasing an additional 3,100 shares during the last quarter. Municipal Employees Retirement System of Michigan increased its position in shares of AngioDynamics by 3.0% during the 1st quarter. Municipal Employees Retirement System of Michigan now owns 7,200 shares of the medical instruments supplier’s stock worth $125,000 after purchasing an additional 210 shares during the last quarter. Mason Street Advisors LLC increased its position in shares of AngioDynamics by 8.5% during the 1st quarter. Mason Street Advisors LLC now owns 7,470 shares of the medical instruments supplier’s stock worth $130,000 after purchasing an additional 584 shares during the last quarter. Finally, BlueCrest Capital Management Ltd acquired a new stake in shares of AngioDynamics during the 1st quarter worth about $175,000. 95.42% of the stock is owned by hedge funds and other institutional investors.

Shares of AngioDynamics, Inc. (ANGO) opened at 17.46 on Thursday. AngioDynamics, Inc. has a 12 month low of $14.80 and a 12 month high of $18.85. The company’s 50 day moving average price is $17.40 and its 200-day moving average price is $16.37. The firm has a market capitalization of $641.04 million, a P/E ratio of 176.36 and a beta of 1.12.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Thursday, September 28th. The medical instruments supplier reported $0.12 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.16 by ($0.04). The business had revenue of $85.40 million for the quarter, compared to analysts’ expectations of $86.12 million. AngioDynamics had a return on equity of 4.83% and a net margin of 1.64%. The business’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.17 earnings per share. On average, equities analysts predict that AngioDynamics, Inc. will post $0.66 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/10/19/angiodynamics-inc-ango-position-lessened-by-jpmorgan-chase-co.html.

In other news, CEO James C. Clemmer acquired 5,000 shares of the business’s stock in a transaction dated Friday, July 21st. The shares were bought at an average cost of $15.79 per share, for a total transaction of $78,950.00. Following the acquisition, the chief executive officer now directly owns 86,683 shares in the company, valued at approximately $1,368,724.57. The purchase was disclosed in a filing with the SEC, which is available through this link. Company insiders own 1.80% of the company’s stock.

ANGO has been the subject of a number of recent analyst reports. BidaskClub raised AngioDynamics from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Zacks Investment Research raised AngioDynamics from a “sell” rating to a “hold” rating in a research report on Monday, August 14th. Barclays PLC cut their price objective on AngioDynamics from $17.00 to $16.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 19th. KeyCorp reissued a “hold” rating on shares of AngioDynamics in a research report on Friday, September 29th. Finally, Cantor Fitzgerald raised their price objective on AngioDynamics from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 4th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $18.60.

AngioDynamics Profile

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Institutional Ownership by Quarter for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.